Tavo Biotherapeutics, a biotech firm focused on ophthalmology, has closed a $17.0M Series A funding round. The capital infusion will advance its pipeline of innovative treatments for critical unmet needs in eye care.
The company is developing TAV-001, a potential disease-modifying therapy for glaucoma-related neurodegeneration, which is slated to enter Phase 1 clinical trials in 2025. Its second program, TAV-002, targets retinal diseases like diabetic retinopathy and age-related macular degeneration, with IND-enabling activities already underway.
.png&w=3840&q=75)
